Conditions: Type 2 Diabetes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1282
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Saxagliptin intervention 2: Metformin XR intervention 3: Dapagliflozin intervention 4: Placebo matching with Dapagliflozin intervention 5: Placebo matching with Saxagliptin
Intervention descriptions: intervention 1: Tablets, Oral, 5mg , Once daily, 24 weeks intervention 2: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks intervention 3: Tablets, Oral, 10mg , Once daily, 24 weeks intervention 4: Tablets, Oral, 0mg, Once daily, 24 weeks intervention 5: Tablets, Oral, 0mg, Once daily, 24 weeks

Protocol document: